117 related articles for article (PubMed ID: 26334457)
1. Intensification of maintenance therapy with infliximab in ulcerative colitis.
Casellas F
Rev Esp Enferm Dig; 2015 Sep; 107(9):525-6. PubMed ID: 26334457
[No Abstract] [Full Text] [Related]
2. Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis.
Fernández-Salazar L; Barrio J; Muñoz F; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; González-Redondo G; Fernández N; Santos F; Sánchez-Ocaña R; Joao D;
Rev Esp Enferm Dig; 2015 Sep; 107(9):527-33. PubMed ID: 26334458
[TBL] [Abstract][Full Text] [Related]
3. Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus.
Ben-Horin S; Ungar B; Eliakim R; Langevitz P
J Crohns Colitis; 2016 Jun; 10(6):752-3. PubMed ID: 26826571
[No Abstract] [Full Text] [Related]
4. Immune thrombocytopenia in ulcerative colitis.
Casella G; Antonelli E; Villanacci V; Salemme M; Di Bella C; Baldini V; Bassotti G
Tech Coloproctol; 2016 Jul; 20(7):499-500. PubMed ID: 27137208
[No Abstract] [Full Text] [Related]
5. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.
Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F
Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433
[TBL] [Abstract][Full Text] [Related]
6. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
7. [A case of a simple ulcer associated with ulcerative colitis that demonstrated a good clinical response to infliximab].
Kishi M; Sou S; Ishihara H; Terabe H; Yasaka M; Kuhara K; Takeda T; Shimokoube M; Morimitsu Y; Miyazono K
Nihon Shokakibyo Gakkai Zasshi; 2015; 112(9):1682-8. PubMed ID: 26346358
[TBL] [Abstract][Full Text] [Related]
8. Assessment of induction therapy with infliximab in children with moderate to severe ulcerative colitis: a multi-center study.
Szychta M; Wiernicka A; Dądalski M; Landowski P; Klincewicz B; Karolewska-Bochenek K; Czaja-Bulsa G; Jarocka-Cyrta E; Korczowski B; Sladek M; Kierkus J
Dev Period Med; 2016; 20(3):205-211. PubMed ID: 27941190
[TBL] [Abstract][Full Text] [Related]
9. Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
Cardile S; Candusso M; Papadatou B; Bracci F; Knafelz D; Torre G
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):736. PubMed ID: 28441268
[No Abstract] [Full Text] [Related]
10. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy.
Aloi M; D'Arcangelo G; Capponi M; Nuti F; Vassallo F; Civitelli F; Oliva S; Pagliaro G; Cucchiara S
Dig Liver Dis; 2015 Jun; 47(6):455-9. PubMed ID: 25733340
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients.
Pérez-Pitarch A; Ferriols-Lisart R; Alós-Almiñana M; Mínguez-Pérez M
Rev Esp Enferm Dig; 2015 Mar; 107(3):137-42. PubMed ID: 25733037
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
[TBL] [Abstract][Full Text] [Related]
13. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine-Induced Sweet Syndrome Treated With Infliximab.
Patel AV; Jotwani PM; Sultan KS
Am J Ther; 2019; 26(5):e616-e617. PubMed ID: 30074533
[No Abstract] [Full Text] [Related]
15. Cyclosporine for severe steroid-refractory ulcerative colitis: commenting the comment.
Actis GC; Pellicano R
Minerva Gastroenterol Dietol; 2018 Sep; 64(3):190-192. PubMed ID: 29327818
[No Abstract] [Full Text] [Related]
16. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis.
Nishida Y; Hosomi S; Yamagami H; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Fujiwara Y
PLoS One; 2017; 12(1):e0169845. PubMed ID: 28076386
[TBL] [Abstract][Full Text] [Related]
18. A Rare But Devastating Dermatologic Manifestation of Ulcerative Colitis.
Kuftinec GN; Lim JE; Yarur AJ
Gastroenterology; 2023 May; 164(6):883-886. PubMed ID: 36336001
[No Abstract] [Full Text] [Related]
19. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
